Literature DB >> 12197900

Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis.

Y M van der Geld1, A T J Tool, J Videler, M de Haas, J W Cohen Tervaert, C A Stegeman, P C Limburg, C G M Kallenberg, D Roos.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3) are strongly associated with Wegener's granulomatosis (WG) and are thought to be involved in its pathogenesis. Levels of PR3-ANCA do not always correspond to clinical disease activity. To investigate the relationship between functional effects of PR3-ANCA and disease activity, we tested the effect of IgG samples from sera of 43 WG patients, taken during active disease or remission, for their capacity to interfere with the proteolytic activity of PR3. Furthermore, longitudinal sera of seven WG patients were included. The enzymatic activity of PR3 was determined (1) with casein or with a small synthetic substrate and (2) by complexation of PR3 with alpha1-antitrypsin (alpha1-AT). With a fixed concentration (100 microg/ml) of IgG, PR3-ANCA from patients during an active phase of WG had a higher inhibitory capacity towards the proteolytic activity of PR3 and complexation of PR3 with alpha1-AT than did PR3-ANCA from WG patients during remission. However, the number of PR3-ANCA units that gave 50% inhibition of the PR3 enzymatic activity and its complexation with alpha1-AT was lower for patients during remission than for patients during an active phase of WG, indicating a stronger inhibitory capacity at a molar base. In conclusion, PR3-ANCA from patients during remission had a relatively higher inhibitory capacity towards the enzymatic activity of PR3 than PR3-ANCA from patients during an active phase. This may indicate that during active disease the ANCA titre is increased, but the number of active ANCA molecules that recognize the enzyme-inhibiting epitopes is not increased.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197900      PMCID: PMC1906460          DOI: 10.1046/j.1365-2249.2002.01926.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

2.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies.

Authors:  J W Tervaert; F J van der Woude; A S Fauci; J L Ambrus; J Velosa; W F Keane; S Meijer; M van der Giessen; G K van der Hem; T H The
Journal:  Arch Intern Med       Date:  1989-11

Review 3.  Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; M van der Giessen; M G Huitema; G K van der Hem; T H The; A E von dem Borne; C G Kallenberg
Journal:  Kidney Int       Date:  1990-02       Impact factor: 10.612

4.  Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site.

Authors:  M E Griffith; A Coulthart; S Pemberton; A J George; C D Pusey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.

Authors:  J L Niles; R T McCluskey; M F Ahmad; M A Arnaout
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

6.  Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies.

Authors:  Y M van der Geld; W Oost-Kort; P C Limburg; U Specks; C G Kallenberg
Journal:  J Immunol Methods       Date:  2000-10-20       Impact factor: 2.303

7.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

8.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

9.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme.

Authors:  J Lüdemann; B Utecht; W L Gross
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis.

Authors:  Maria C Cid; Marta Segarra; Ana García-Martínez; Jose Hernández-Rodríguez
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

2.  Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.

Authors:  B F Bruner; E S Vista; D M Wynn; J B Harley; J A James
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

3.  Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding.

Authors:  Greg Byrne; Fergus Ryan; John Jackson; Con Feighery; Jacinta Kelly
Journal:  Gut       Date:  2006-08-25       Impact factor: 23.059

4.  Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.

Authors:  Francisco Silva; Amber M Hummel; Dieter E Jenne; Ulrich Specks
Journal:  J Autoimmun       Date:  2010-12       Impact factor: 7.094

5.  Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)-induced ANCA positive vasculitis are associated with disease activity.

Authors:  F Yu; M-H Zhao; Y-K Zhang; Y Zhang; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 6.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Authors:  Brice Korkmaz; Jérôme Jaillet; Marie-Lise Jourdan; Alexandre Gauthier; Francis Gauthier; Sylvie Attucci
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

8.  Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.

Authors:  Agnieszka A Rarok; Ymke M van der Geld; Coen A Stegeman; Pieter C Limburg; Cees G M Kallenberg
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

Review 9.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

10.  4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis.

Authors:  Jérôme Granel; Roxane Lemoine; Eric Morello; Yann Gallais; Julie Mariot; Marion Drapeau; Astrid Musnier; Anne Poupon; Martine Pugnière; Seda Seren; Dalila Nouar; Valérie Gouilleux-Gruart; Hervé Watier; Brice Korkmaz; Cyrille Hoarau
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.